Indraprastha Medical [INDRAMEDCO] vs Dr. Agarwal's Eye [DRAGARWQ] Detailed Stock Comparison

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Indraprastha Medical wins in 13 metrics, Dr. Agarwal's Eye wins in 7 metrics, with 0 ties. Indraprastha Medical appears stronger overall.

View Metrics Details

Vital Metrics Comparison

MetricIndraprastha MedicalDr. Agarwal's EyeBetter
P/E Ratio (TTM)24.1340.35Indraprastha Medical
Price-to-Book Ratio7.0011.14Indraprastha Medical
Debt-to-Equity Ratio5.49158.94Indraprastha Medical
PEG Ratio1.611.81Indraprastha Medical
EV/EBITDA15.3620.32Indraprastha Medical
Profit Margin (TTM)12.21%13.96%Dr. Agarwal's Eye
Operating Margin (TTM)17.25%22.71%Dr. Agarwal's Eye
EBITDA Margin (TTM)17.25%22.71%Dr. Agarwal's Eye
Return on Equity26.98%26.07%Indraprastha Medical
Return on Assets (TTM)18.90%8.91%Indraprastha Medical
Free Cash Flow (TTM)$1.20B$-83.80MIndraprastha Medical
Dividend Yield0.95%0.11%Indraprastha Medical
1-Year Return9.20%4.92%Indraprastha Medical
Price-to-Sales Ratio (TTM)3.045.64Indraprastha Medical
Enterprise Value$38.89B$26.43BIndraprastha Medical
EV/Revenue Ratio2.836.38Indraprastha Medical
Gross Profit Margin (TTM)38.19%77.64%Dr. Agarwal's Eye
Revenue per Share (TTM)$150$881Dr. Agarwal's Eye
Earnings per Share (Diluted)$18.86$123.07Dr. Agarwal's Eye
Beta (Stock Volatility)0.57-0.36Dr. Agarwal's Eye
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends

Indraprastha Medical vs Dr. Agarwal's Eye Stock Performance Analysis

Loading Price Chart...

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Indraprastha Medical1.51%3.48%-3.24%-7.50%14.75%-14.65%
Dr. Agarwal's Eye-0.31%2.98%9.84%14.47%16.54%-23.53%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Indraprastha Medical9.20%642.22%819.28%590.66%890.15%874.50%
Dr. Agarwal's Eye4.92%358.10%1,895.43%3,647.65%6,296.19%14,656.04%

News Based Sentiment: Indraprastha Medical vs Dr. Agarwal's Eye

Indraprastha Medical

News based Sentiment: MIXED

September presented a mixed bag for Indraprastha Medical, with slightly disappointing Q2 results countered by a consistent dividend and an attractive valuation. While profitability declined, the company maintains a commitment to shareholder returns and appears undervalued compared to its peers, creating a complex investment picture.

View Indraprastha Medical News Sentiment Analysis

Dr. Agarwal's Eye

News based Sentiment: POSITIVE

September was a strong month for Dr. Agarwal's, marked by impressive financial results, a commitment to shareholder returns through a 35% dividend, and increasing institutional investor confidence. Long-term projections from Walletinvestor.com further reinforce a positive investment outlook, suggesting significant potential for future growth.

View Dr. Agarwal's Eye News Sentiment Analysis

Performance & Financial Health Analysis: Indraprastha Medical vs Dr. Agarwal's Eye

MetricINDRAMEDCODRAGARWQ
Market Information
Market Cap i₹42.43B₹23.46B
Market Cap CategorySmall capSmall cap
10 Day Avg. Volume i115,4701,476
90 Day Avg. Volume i212,8623,361
Last Close₹462.40₹4,950.65
52 Week Range₹307.25 - ₹572.00₹3,500.00 - ₹7,300.00
% from 52W High-19.16%-32.18%
All-Time High₹572.00 (Jan 06, 2025)₹7,300.00 (Dec 30, 2024)
% from All-Time High-19.16%-32.18%
Growth Metrics
Quarterly Revenue Growth0.05%0.17%
Quarterly Earnings Growth0.15%0.22%
Financial Health
Profit Margin (TTM) i0.12%0.14%
Operating Margin (TTM) i0.17%0.23%
Return on Equity (TTM) i0.27%0.26%
Debt to Equity (MRQ) i5.49158.94
Cash & Liquidity
Book Value per Share (MRQ)₹65.04₹445.96
Cash per Share (MRQ)₹35.08₹52.76
Operating Cash Flow (TTM) i₹1.78B₹738.70M
Levered Free Cash Flow (TTM) i₹1.61B₹546.50M
Dividends
Last 12-Month Dividend Yield i0.95%0.11%
Last 12-Month Dividend i₹4.50₹5.00

Valuation & Enterprise Metrics Analysis: Indraprastha Medical vs Dr. Agarwal's Eye

MetricINDRAMEDCODRAGARWQ
Price Ratios
P/E Ratio (TTM) i24.1340.35
Forward P/E i182.00510.88
PEG Ratio i1.611.81
Price to Sales (TTM) i3.045.64
Price to Book (MRQ) i7.0011.14
Market Capitalization
Market Capitalization i₹42.43B₹23.46B
Enterprise Value i₹38.89B₹26.43B
Enterprise Value Metrics
Enterprise to Revenue i2.836.38
Enterprise to EBITDA i15.3620.32
Risk & Other Metrics
Beta i0.57-0.36
Book Value per Share (MRQ) i₹65.04₹445.96

Financial Statements Comparison: Indraprastha Medical vs Dr. Agarwal's Eye

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)INDRAMEDCODRAGARWQ
Revenue/Sales i₹3.65B₹1.17B
Cost of Goods Sold i₹2.26B₹261.40M
Gross Profit i₹1.39B₹907.80M
Research & Development iN/AN/A
Operating Income (EBIT) i₹629.70M₹265.50M
EBITDA i₹800.50M₹379.30M
Pre-Tax Income i₹683.10M₹231.90M
Income Tax i₹168.50M₹59.30M
Net Income (Profit) i₹514.60M₹172.60M

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)INDRAMEDCODRAGARWQ
Cash & Equivalents i₹614.80M₹111.60M
Total Current Assets i₹4.31B₹559.40M
Total Current Liabilities i₹1.79B₹869.80M
Long-Term Debt i₹305.40M₹3.06B
Total Shareholders Equity i₹5.97B₹2.10B
Retained Earnings i₹4.75B₹1.99B
Property, Plant & Equipment i₹2.60B₹1.37B

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)INDRAMEDCODRAGARWQ
Operating Cash Flow iN/AN/A
Capital Expenditures iN/AN/A
Free Cash Flow iN/AN/A
Debt Repayment iN/AN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricINDRAMEDCODRAGARWQ
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Average Daily Volume (10 Day) i115,4701,476
Average Daily Volume (90 Day) i212,8623,361
Shares Outstanding i91.67M4.70M
Float Shares i41.01M1.11M
% Held by Insiders i0.58%0.81%
% Held by Institutions i0.03%0.02%

Dividend Analysis & Yield Comparison: Indraprastha Medical vs Dr. Agarwal's Eye

MetricINDRAMEDCODRAGARWQ
Last 12-Month Dividend i₹4.50₹5.00
Last 12-Month Dividend Yield i0.95%0.11%
3-Year Avg Annual Dividend i₹4.00₹4.50
3-Year Avg Dividend Yield i1.26%0.12%
3-Year Total Dividends i₹12.00₹13.50
Ex-Dividend DateSep 18, 2025Nov 08, 2024